Approaches for Developing Novel Microtubule Targeting Agents (MTAs) for Therapeutic Exploitation

Author(s): Aswini Krishnan, James Wilson, Hing Y. Leung

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 19 , 2012

Become EABM
Become Reviewer
Call for Editor


The microtubule (MT) represents a highly validated target for therapy. Insights into the complex nature of the dynamic microtubule physiology will provide the basis for developing novel microtubule targeting agents with enhanced efficacy and minimised toxicity. In this article, with an emphasis on translational applications, we have summarised relevant aspects of tubulin physiology in the context of developing MT binding agents as therapeutic agents. Case studies were included to illustrate therapeutic developments in prostate cancer and current strategies to discover novel agents or targets for therapy.

Keywords: Microtubule (MT), microtubule associated proteins (MAPs), microtubule targeting agents (MTAs), chemotherapy, tubulin heterodimers, polymerases, angiogenesis, neutropenia, p21-activated kinase 6 (PAK6), prostate cancer

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 02 May, 2012
Page: [2804 - 2810]
Pages: 7
DOI: 10.2174/138161212800626111
Price: $65

Article Metrics

PDF: 22